Plain-English translation of NCT07095439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to treat rectal cancer by combining chemotherapy (CAPEOX or FOLFOX6), short-course radiation therapy, and surgery in a specific sequence called "total neoadjuvant treatment." The idea is to attack the cancer from multiple angles before surgery, which may help prevent the cancer from spreading and improve your chances of survival. Researchers want to see if this approach is more effective and causes fewer side effects than standard treatments.
Rectal cancer often comes back as distant spread even after standard treatment, and chemotherapy given after surgery doesn't always work well because surgery itself can be hard on the body. This trial tests whether giving the medication before surgery—along with radiation—might better prevent spread and help more patients tolerate the full treatment.
You likely qualify if…
You likely don't qualify if…
You would receive four cycles of chemotherapy, then short-course radiation therapy over one week, followed by two more cycles of chemotherapy. About 8 to 12 weeks after radiation, you would have surgery to remove the cancer. Throughout this time, you'll have regular doctor visits, blood tests, and imaging scans to monitor your progress. The entire treatment takes several months from start to finish.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Egypt